City of Hope
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From City of Hope
BioMed X teams with J&J on inflammation, drug delivery research. Stem cell firm Calidi inks licensing deals with U. of Chicago, City of Hope and Northwestern. MD Anderson teams with Blueprint and Hummingbird.
The intellectual property, also held by Eureka, may offer a new pathway for treating relapsed MM patients. Sorrento inks cancer partnerships with Karolinska Institutet and Mayo Clinic.
Taysha gains control of GAN candidate and program; BI licenses COMT inhibitors from Lieber Institute; plus three new gene therapy-driven tie-ups between biopharma and academia.
NIH’s National Cancer Institute licensed two experimental cancer therapies in the past month to biopharma firms, leading a heavy slate of cancer-focused tech transfer deal-making.
- Academic and Research Institutions
- Other Names / Subsidiaries
- City of Hope Obligated Group
- City of Hope National Medical Center